In the News
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer commonly driven by activating KRASmutations and TP53 alterations. While TP53 missense mutations are known to disrupt the tumor-suppressive functions of wild-type p53, their potential gain-of-function (GOF) roles remain less well understood. In this study, we investigated whether TP53 missense mutations contribute to tumor progression through GOF mechanisms, and assessed their impact on cancer cell-intrinsic transcriptional programs as well as the composition and function of the tumor immune microenvironment (TME) in PDAC.
Rakesh Jain, PhD, director of the Edwin Steele Laboratories for Tumor Biology in the Department of Radiation Oncology at Massachusetts General Hospital and Andrew Werk Professor of Radiation Oncology at Harvard Medical School, is senior and corresponding author of a paper published in the Journal for ImmunoTherapy of Cancer, “IL-1β Blockade Prevents Cardiotoxicity and Improves Efficacy of Immune Checkpoint Blockers and Chemotherapy against Pancreatic Cancer in Mice with Obesity.
The 2025 AACR Award for Lifetime Achievement in Cancer Research will be presented to Rakesh K. Jain, PhD, Fellow of the AACR Academy, during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois.
Congratulations, Dr. Jain!!
Read the article here
